4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028

4D Molecular Therapeutics, Inc.

2025-Q1 EPS reported -$0.86 revenue$14,000

Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.
Cash $458M (down from $505M Dec 2024); expected to fund operations into 2028.
First patients enrolled in 4D-150 Phase 3 (4FRONT-1) in wet AMD; 4FRONT-2 starts Q3 2025; topline H2 2027.
FDA RMAT designation for 4D-150 in DME; FDA aligned on single Phase 3 trial for BLA.
Pipeline focused on 4D-150 and 4D-710; paused/terminated 4D-175, 4D-725, 4D-310, 4D-110, 4D-125.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.